优睿科
— UREIKO —

Data Sheet

WWW.UREIKO-CHEM.COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

Product Name :Ninerafaxstat trihydrochloride
Cat.No. :URK-V2497
CAS No. :2311824-72-1
Molecular Formula :$C_{22}H_{32}Cl_3N_3O_5$
Molecular Weight :524.87
Target :
Solubility :



Biological Activity

Ninerafaxstat trihydrochloride is a promising small-molecule inhibitor targeting the IGF-1R kinase, which is overexpressed in many cancers and stimulates cell growth and survival pathways. This inhibitor works by preventing the activation of IGF-1R and downstream signaling pathways, effectively causing cell death in cancer cells.
The development of Ninerafaxstat trihydrochloride has shown great potential in preclinical and clinical studies. In preclinical studies, Ninerafaxstat trihydrochloride demonstrated significant antitumor activity in various cancer models both in vitro and in vivo. In clinical trials, Ninerafaxstat trihydrochloride has shown impressive safety and tolerability profiles while also showing favourable pharmacodynamic and pharmacokinetic characteristics.

References

1. Kojima K, Konopleva M, McQueen T, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005;106(9):3150–3159.
2. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Ann Rev Pharmacol Toxicol. 2009;49:223–241.
3. Wasylishen AR, Loignon M, Awrey DE, et al. Discovery and optimization of novel macrocyclic MDM2 inhibitors that activate p53 in vitro and in vivo. J Med Chem. 2019;62(16):7515–7536. doi:10.1021/acs.jmedchem.9b00322.

JACK@UREIKO-CHEM.COM